

A novel peptide synthesis using fluororous chemistry

Mamoru Mizuno, Kohtaro Goto, Tsuyoshi Miura, Daisuke Hosaka and Toshiyuki Inazu*

The Noguchi Institute, 1-8-1, Kaga, Itabashi-ku, Tokyo 173-0003, Japan. E-mail: inz@noguchi.or.jp

Received (in Cambridge, UK) 30th January 2003, Accepted 3rd March 2003

First published as an Advance Article on the web 18th March 2003

Three new fluororous supports for peptide synthesis, *i.e.*, the trialkoxybenzhydryl-type (6), the Wang-type (7) and the *tert*-butyl-type support (8), were prepared. A bioactive peptide TRH was easily synthesized by an Fmoc strategy using the benzhydryl-type fluororous support with fluororous chemistry.

Usually, peptides are easily prepared by solid-phase synthesis. Solid-phase synthesis allows for very simple product isolation by filtration, however, the solid-phase method suffers from some serious disadvantages, such as reduced reactivity and the inability to monitor the reaction by TLC, NMR, and mass spectrometry.

Recently, fluororous chemistry has been studied in several fields such as catalytic chemistry, combinatorial chemistry, parallel synthesis.¹ A fluororous (highly fluorinated) solvent is immiscible in an organic solution, and a fluororous compound partitions out of an organic phase and into a fluororous phase. Therefore a fluororous compound is readily separated from nonfluorinated compounds by a simple “fluororous/organic” extraction. Similar to solid-phase synthesis, fluororous synthesis does not resort to chromatography. Since a fluororous compound is also soluble in not only fluororous solvents but also common organic solvents, the fluororous reaction can be carried out in common organic solvents. Therefore, the strategy of “fluororous synthesis” is designed to combine the advantages of solid-phase synthesis with those of traditional organic synthesis in the liquid-phase synthesis (Fig. 1). Recently, we reported oligosaccharide synthesis using fluororous synthesis.²

In this study, we synthesized several fluororous supports suitable for peptide synthesis in fluororous chemistry, such as the trialkoxybenzhydryl-type 6, Wang-type 7 and *tert*-butyl-type fluororous support 8. We also prepared a bioactive peptide TRH (thyrotropin-releasing hormone)³ using fluororous chemistry.





Fig. 1 Concept of peptide synthesis using fluororous chemistry.

The synthetic route of the three fluororous supports for peptide synthesis 6–8 is shown in Scheme 1. The highly fluorinated carboxylic acid, Hfb-OH⁴ (Fig. 2), was coupled with mono-Fmoc ethylenediamine using PyBOP as the coupling reagent in the mixed solvent, C₄F₉OEt⁵ and CH₂Cl₂. The reaction mixture was partitioned with a fluororous solvent FC-72⁶ and MeCN (or MeOH). Excess reagents were extracted with the organic layer. From the FC-72 layer, the fluororous compound 1 was obtained. The Fmoc group of 1 was cleaved by 5% piperidine/FC-72–DMF solution or 10% Et₂NH/FC72–DMF solution. In the partition step with FC-72 and MeCN (or MeOH), a trace amount of these secondary amines was partitioned into the FC-72 layer. However, Et₂NH is removed during the evaporation of FC-72, because the boiling point of Et₂NH (55 °C) is almost same as that of FC-72 (56 °C). When using piperidine, the fluororous layer was washed with aqueous citric acid to remove the piperidine.



Scheme 1 Synthesis of fluororous supports for peptide synthesis. (a) Fmoc-NH(CH₂)₂NH₂ HCl salt, PyBOP, (*i*-Pr)₂NEt/C₄F₉OEt–CH₂Cl₂, RT, 1 h; (b) 5% piperidine or 10% Et₂NH/DMF–FC-72, RT, 30 min; (c) 2, PyBOP, (*i*-Pr)₂NEt/C₄F₉OEt–CH₂Cl₂, RT, 1 h; (d) cat. NaOMe/MeOH, RT, 30 min.





Fig. 2 Structure of Hfb-OH.

From the FC-72 layer, the fluorous compound **2** was obtained. The coupling of compound **2** with a linker reagent **3–5** gave the trialkoxybenzhydryl-type **6**,⁷ Wang-type **7**⁸ and *tert*-butyl-type fluorous supports **8**,⁹ respectively, in excellent yield by only one purification as the final step.

Using the fluorous support **6**, the tripeptide TRH was prepared by the Fmoc strategy (Scheme 2). The Fmoc group was cleaved by 5% piperidine/FC-72–DMF solution, and the coupling was carried out using PyBOP as the coupling reagent in the mixed solvent, C₄F₉OEt⁵ and CH₂Cl₂. The partition step was performed as described above. A 4-fold excess of the amino acid derivative was used in each coupling reaction. The peptide with fluorous support **6** was treated with TFA containing 2.5% H₂O and 2.5% 1,4-butanedithiol to cleave the peptide from the fluorous support and remove the side-chain protecting group. After partitioning between FC-72, water, and toluene, the desired peptide was extracted into the water layer. The derivative of the fluorous support and other reagents were extracted with the FC-72 layer and toluene layer, respectively. The HPLC chart of the crude peptide is shown in Fig. 3. After purification of the water layer by RP-HPLC, the TRH was obtained in 62% yield in 7 reaction steps by only one purification as the final step.¹⁰

In conclusion, a peptide was very easily prepared using fluorous chemistry. Each synthetic intermediate was able to be easily purified by simple FC-72/organic solvent extraction and monitored by NMR, mass spectrometry and TLC. Fluorous chemistry has become an excellent strategic alternative to solid-phase synthesis.

This work was partly supported by a Grant-in-Aid for Scientific Research (C) (No. 13680680), a Grant-in-Aid for



Scheme 2 Synthesis of TRH using fluorous chemistry.




Fig. 3 HPLC profile of crude TRH synthesized by fluorous synthesis.¹¹

Encouragement of Young Scientists (No. 13771349) from the Japan Society for the Promotion of Science, and Takeda Science Foundation. This work was performed through the Noguchi Fluorous Project by our institute.

Notes and references

- Z. Luo, Q. Zhang, Y. Oderatoshi and D. P. Curran, *Science*, 2001, **291**, 1766; A. G. M. Barrett, D. C. Braddock, D. Catterick, D. Chadwick, J. P. Henschke and R. M. McKinnell, *Synlett*, 2000, 847; D. P. Curran, *Pure Appl. Chem.*, 2000, **72**, 1649; D. P. Curran, *Angew. Chem., Int. Ed.*, 1998, **37**, 1174; A. Studer, S. Hadida, R. Ferritto, S. Y. Kim, P. Jeger, P. Wipf and D. P. Curran, *Science*, 1997, **275**, 823.
- T. Miura, Y. Hirose, M. Ohmae and T. Inazu, *Org. Lett.*, 2001, **3**, 3947.
- C. Hatanaka, M. Obayashi, O. Nishimura, N. Toukai and M. Fujino, *Biochem. Biophys. Res. Commun.*, 1974, **60**, 1345.
- T. Miura, K. Goto, D. Hosaka and T. Inazu, *Angew. Chem., Int. Ed.*, in press.
- C₄F₉OEt is a commercially available fluorocarbon solvent (3M, Tokyo), which is called Novec™ HFE-7200.
- FC-72 is a commercially available fluorocarbon solvent (3M, Tokyo), which consists of perfluorohexane (C₆F₁₄) isomers and is called Fluorinert™ FC-72.
- Compound **6**: amorphous solid, ¹H NMR (600 MHz, CDCl₃) δ = 1.81–1.90 (m, 10H), 2.06–2.17 (m, 15H), 2.32–2.78 (m, 17H), 3.37–3.44 (m, 20H), 3.57–3.67 (m, 8H), 3.74 (s, 3H), 3.80 (s, 3H), 4.23 (br, 1H), 4.41 (d, 1H, 6.9 Hz), 4.46 (s, 2H), 5.91 (m, 1H), 6.03 (m, 1H), 6.47 (m, 2H), 6.84 (m, 2H), 7.09 (m, 1H), 7.16 (m, 3H), 7.30 (m, 2H), 7.39 (m, 3H), 7.58 (d, 2H, J = 6.9 Hz), 7.76 (d, 2H, J = 6.9 Hz). MALDI-TOF MASS: Calcd. for C₁₂₁H₉₈F₁₀₂N₁₀NaO₁₄ [M + Na⁺]: 3876.96, found: 3875.05.
- Compound **7**: amorphous solid, ¹H NMR (600 MHz, CDCl₃) δ = 1.85–1.91 (m, 10H), 2.08–2.16 (m, 11H), 2.33–2.69 (m, 19H), 3.34–3.67 (m, 31H), 4.49 (s, 2H), 4.61 (s, 2H), 6.91–6.92 (m, 2H), 7.30–7.32 (m, 2H). MALDI-TOF MASS: Calcd. for C₉₈H₇₉F₁₀₂N₉NaO₁₁ [M + Na⁺]: 3519.55, found: 3516.94.
- Compound **8**: amorphous solid, ¹H NMR (600 MHz, CDCl₃) δ = 1.27 (s, 6H), 1.82–1.92 (m, 11H), 2.04–2.23 (m, 11H), 2.36–2.82 (m, 21H), 3.41–3.46 (m, 21H), 3.59–3.68 (m, 9H). MALDI-TOF MASS: Calcd. for C₉₄H₇₉F₁₀₂N₉NaO₁₀ [M + Na⁺]: 3455.51, found: 3455.07.
- Amino acid analysis. Glu 1.02 (1), Pro 1.00 (1), His 0.98 (1). MALDI-TOF MASS: Calcd for C₁₆H₂₃N₆O₄ [M + H⁺]: 363.39, found: 363.41.
- Elution conditions of crude peptide: column, GL Sciences Inertsil ODS-3 (4.6 × 250 mm); eluent, 2–20% MeCN/H₂O–0.1% TFA (v/v/v), 20 min; flow rate, 1.0 mL min⁻¹.